Literature DB >> 16891977

Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years.

Kern Singh1, Joseph D Smucker, Sanjitpal Gill, Scott D Boden.   

Abstract

INTRODUCTION: This study determines whether recombinant human bone morphogenetic protein-2 (rhBMP-2) (12 mg at the rate of 1.5 mg/mL) delivered on an absorbable collagen sponge with an added bulking agent can increase posterolateral lumbar spine fusion success rates and decrease time for fusion with autogenous bone grafts.
METHOD: A prospective, single institution, clinical case-matched, radiographic, cohort study was undertaken. A total of 52 patients underwent posterolateral lumbar arthrodesis with pedicle screw instrumentation. The experimental group (n=41) underwent placement of Iliac crest bone graft (ICBG) with InFUSE (12 mg/level at the rate of 1.5 mg/mL). The control group (n=11) consisted of sex-matched patients, consecutively collected over the same time period with an instrumented posterolateral arthrodesis and ICBG placed in the intertransverse space. OUTCOME MEASURES: Thin-cut (2 mm) axial, coronal, and sagittal reconstructions were blindly evaluated for evidence of bridging bone and cortication of the fusion mass by 3 separate reviewers. Fusions were graded and an overall score was given to the quality of the fusion mass.
RESULTS: Fifty patients (ICBG alone n=11; ICBG/rhBMP-2 n=39) were available for CT evaluation at 2-year follow-up. An overall 97% (68/70 levels; Definite+Probably Fused) fusion rate in the rhBMP-2 group was achieved as compared to the 77% fusion rate (17/22 levels) in the ICBG alone group (P<0.05). In the rhBMP-2 group, 92% of the patients (36/39 patients) received an overall excellent subjective fusion rating as compared to 27% (3/11) in the control group (P<0.05). There was no computed tomographic evidence of soft-tissue ossification, dural ossification, or laminar bone regrowth in any patient.
CONCLUSIONS: The adjunctive use of rhBMP-2 and ICBG seems to be safe and results in significantly larger and more consistent posterolateral fusion masses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891977     DOI: 10.1097/00024720-200608000-00008

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  27 in total

1.  The efficacy of rhBMP-2 versus autograft for posterolateral lumbar spine fusion in elderly patients.

Authors:  Kwang-Bok Lee; Cyrus E Taghavi; Margaret S Hsu; Kyung-Jin Song; Jeong Hyun Yoo; Gun Keorochana; Stephanie S Ngo; Jeffrey C Wang
Journal:  Eur Spine J       Date:  2009-12-30       Impact factor: 3.134

2.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

3.  Comparing the process of creeping substitution between allograft bone and local bone grafting in lumbar interbody fusion.

Authors:  Hui Huang; Chun Jiang; ZhenZhou Feng; Xiaoxing Jiang
Journal:  Eur Spine J       Date:  2014-05-31       Impact factor: 3.134

4.  Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.

Authors:  Stéphane Litrico; Tristan Langlais; Florent Pennes; Antoine Gennari; Philippe Paquis
Journal:  Neurosurg Rev       Date:  2017-03-10       Impact factor: 3.042

Review 5.  Growth factors in orthopaedic surgery: demineralized bone matrix versus recombinant bone morphogenetic proteins.

Authors:  Maurice Hinsenkamp; Jean-Francois Collard
Journal:  Int Orthop       Date:  2014-10-22       Impact factor: 3.075

6.  Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion.

Authors:  Kirk Owens; Steven D Glassman; Jennifer M Howard; Mladen Djurasovic; Jonathan L Witten; Leah Y Carreon
Journal:  Eur Spine J       Date:  2010-06-26       Impact factor: 3.134

7.  Fusion in degenerative spondylolisthesis: comparison of osteoconductive and osteoinductive bone graft substitutes.

Authors:  Mark Kurd; Sarah Cohick; Andrew Park; Kasra Ahmadinia; Joseph Lee; Howard An
Journal:  Eur Spine J       Date:  2014-11-05       Impact factor: 3.134

8.  Anabolic therapies.

Authors:  Nancy E Lane; Stuart L Silverman
Journal:  Curr Osteoporos Rep       Date:  2010-03       Impact factor: 5.096

9.  Nitric oxide modulates recombinant human bone morphogenetic protein-2-induced corticocancellous autograft incorporation: a study in rat intertransverse fusion.

Authors:  Ashish D Diwan; Safdar N Khan; Frank P Cammisa; Harvinder S Sandhu; Joseph M Lane
Journal:  Eur Spine J       Date:  2010-01-09       Impact factor: 3.134

10.  Point-counter-point debate: the association between recombinant human bone morphogenetic protein utilization and complications in spine surgery.

Authors:  Kris Siemionow; Eric Sundberg; Marcin Tyrakowski; Sreeharsha V Nandyala; Kern Singh
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.